Management of thyroid disorders during the COVID-19 outbreak: a position statement from the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism (SBEM)

ABSTRACT This position statement was prepared to guide endocrinologists on the best approach to managing thyroid disorders during the coronavirus disease (COVID-19) pandemic. The most frequent thyroid hormonal findings in patients with COVID-19, particularly in individuals with severe disease, are similar to those present in the non-thyroidal illness syndrome and require no intervention. Subacute thyroiditis has also been reported during COVID-19 infection. Diagnosis and treatment of hypothyroidism during the COVID-19 pandemic may follow usual practice; however, should avoid frequent laboratory tests in patients with previous controlled disease. Well-controlled hypo and hyperthyroidism are not associated with an increased risk of COVID-19 infection or severity. Newly diagnosed hyperthyroidism during the pandemic should be preferably treated with antithyroid drugs (ATDs), bearing in mind the possibility of rare side effects with these medications, particularly agranulocytosis, which requires immediate intervention. Definitive treatment of hyperthyroidism (radioiodine therapy or surgery) may be considered in those cases that protective protocols can be followed to avoid COVID-19 contamination or once the pandemic is over. In patients with moderate Graves’ ophthalmopathy (GO) not at risk of visual loss, glucocorticoids at immunosuppressive doses should be avoided, while in those with severe GO without COVID-19 and at risk of vision loss, intravenous glucocorticoid is the therapeutic choice. Considering that most of the thyroid cancer cases are low risk and associated with an excellent prognosis, surgical procedures could and should be postponed safely during the pandemic period. Additionally, when indicated, radioiodine therapy could also be safely postponed as long as it is possible.

Saved in:
Bibliographic Details
Main Authors: Martins,João Roberto M., Villagelin,Danilo G. P., Carvalho,Gisah A., Vaisman,Fernanda, Teixeira,Patrícia F. S., Scheffel,Rafael S., Sgarbi,José A.
Format: Digital revista
Language:English
Published: Sociedade Brasileira de Endocrinologia e Metabologia 2021
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972021000300368
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S2359-39972021000300368
record_format ojs
spelling oai:scielo:S2359-399720210003003682021-07-06Management of thyroid disorders during the COVID-19 outbreak: a position statement from the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism (SBEM)Martins,João Roberto M.Villagelin,Danilo G. P.Carvalho,Gisah A.Vaisman,FernandaTeixeira,Patrícia F. S.Scheffel,Rafael S.Sgarbi,José A. Thyroid disorders hypothyroidism hyperthyroidism, subacute thyroiditis COVID-19 ABSTRACT This position statement was prepared to guide endocrinologists on the best approach to managing thyroid disorders during the coronavirus disease (COVID-19) pandemic. The most frequent thyroid hormonal findings in patients with COVID-19, particularly in individuals with severe disease, are similar to those present in the non-thyroidal illness syndrome and require no intervention. Subacute thyroiditis has also been reported during COVID-19 infection. Diagnosis and treatment of hypothyroidism during the COVID-19 pandemic may follow usual practice; however, should avoid frequent laboratory tests in patients with previous controlled disease. Well-controlled hypo and hyperthyroidism are not associated with an increased risk of COVID-19 infection or severity. Newly diagnosed hyperthyroidism during the pandemic should be preferably treated with antithyroid drugs (ATDs), bearing in mind the possibility of rare side effects with these medications, particularly agranulocytosis, which requires immediate intervention. Definitive treatment of hyperthyroidism (radioiodine therapy or surgery) may be considered in those cases that protective protocols can be followed to avoid COVID-19 contamination or once the pandemic is over. In patients with moderate Graves’ ophthalmopathy (GO) not at risk of visual loss, glucocorticoids at immunosuppressive doses should be avoided, while in those with severe GO without COVID-19 and at risk of vision loss, intravenous glucocorticoid is the therapeutic choice. Considering that most of the thyroid cancer cases are low risk and associated with an excellent prognosis, surgical procedures could and should be postponed safely during the pandemic period. Additionally, when indicated, radioiodine therapy could also be safely postponed as long as it is possible.info:eu-repo/semantics/openAccessSociedade Brasileira de Endocrinologia e MetabologiaArchives of Endocrinology and Metabolism v.65 n.3 20212021-06-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972021000300368en10.20945/2359-3997000000352
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Martins,João Roberto M.
Villagelin,Danilo G. P.
Carvalho,Gisah A.
Vaisman,Fernanda
Teixeira,Patrícia F. S.
Scheffel,Rafael S.
Sgarbi,José A.
spellingShingle Martins,João Roberto M.
Villagelin,Danilo G. P.
Carvalho,Gisah A.
Vaisman,Fernanda
Teixeira,Patrícia F. S.
Scheffel,Rafael S.
Sgarbi,José A.
Management of thyroid disorders during the COVID-19 outbreak: a position statement from the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism (SBEM)
author_facet Martins,João Roberto M.
Villagelin,Danilo G. P.
Carvalho,Gisah A.
Vaisman,Fernanda
Teixeira,Patrícia F. S.
Scheffel,Rafael S.
Sgarbi,José A.
author_sort Martins,João Roberto M.
title Management of thyroid disorders during the COVID-19 outbreak: a position statement from the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism (SBEM)
title_short Management of thyroid disorders during the COVID-19 outbreak: a position statement from the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism (SBEM)
title_full Management of thyroid disorders during the COVID-19 outbreak: a position statement from the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism (SBEM)
title_fullStr Management of thyroid disorders during the COVID-19 outbreak: a position statement from the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism (SBEM)
title_full_unstemmed Management of thyroid disorders during the COVID-19 outbreak: a position statement from the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism (SBEM)
title_sort management of thyroid disorders during the covid-19 outbreak: a position statement from the thyroid department of the brazilian society of endocrinology and metabolism (sbem)
description ABSTRACT This position statement was prepared to guide endocrinologists on the best approach to managing thyroid disorders during the coronavirus disease (COVID-19) pandemic. The most frequent thyroid hormonal findings in patients with COVID-19, particularly in individuals with severe disease, are similar to those present in the non-thyroidal illness syndrome and require no intervention. Subacute thyroiditis has also been reported during COVID-19 infection. Diagnosis and treatment of hypothyroidism during the COVID-19 pandemic may follow usual practice; however, should avoid frequent laboratory tests in patients with previous controlled disease. Well-controlled hypo and hyperthyroidism are not associated with an increased risk of COVID-19 infection or severity. Newly diagnosed hyperthyroidism during the pandemic should be preferably treated with antithyroid drugs (ATDs), bearing in mind the possibility of rare side effects with these medications, particularly agranulocytosis, which requires immediate intervention. Definitive treatment of hyperthyroidism (radioiodine therapy or surgery) may be considered in those cases that protective protocols can be followed to avoid COVID-19 contamination or once the pandemic is over. In patients with moderate Graves’ ophthalmopathy (GO) not at risk of visual loss, glucocorticoids at immunosuppressive doses should be avoided, while in those with severe GO without COVID-19 and at risk of vision loss, intravenous glucocorticoid is the therapeutic choice. Considering that most of the thyroid cancer cases are low risk and associated with an excellent prognosis, surgical procedures could and should be postponed safely during the pandemic period. Additionally, when indicated, radioiodine therapy could also be safely postponed as long as it is possible.
publisher Sociedade Brasileira de Endocrinologia e Metabologia
publishDate 2021
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972021000300368
work_keys_str_mv AT martinsjoaorobertom managementofthyroiddisordersduringthecovid19outbreakapositionstatementfromthethyroiddepartmentofthebraziliansocietyofendocrinologyandmetabolismsbem
AT villagelindanilogp managementofthyroiddisordersduringthecovid19outbreakapositionstatementfromthethyroiddepartmentofthebraziliansocietyofendocrinologyandmetabolismsbem
AT carvalhogisaha managementofthyroiddisordersduringthecovid19outbreakapositionstatementfromthethyroiddepartmentofthebraziliansocietyofendocrinologyandmetabolismsbem
AT vaismanfernanda managementofthyroiddisordersduringthecovid19outbreakapositionstatementfromthethyroiddepartmentofthebraziliansocietyofendocrinologyandmetabolismsbem
AT teixeirapatriciafs managementofthyroiddisordersduringthecovid19outbreakapositionstatementfromthethyroiddepartmentofthebraziliansocietyofendocrinologyandmetabolismsbem
AT scheffelrafaels managementofthyroiddisordersduringthecovid19outbreakapositionstatementfromthethyroiddepartmentofthebraziliansocietyofendocrinologyandmetabolismsbem
AT sgarbijosea managementofthyroiddisordersduringthecovid19outbreakapositionstatementfromthethyroiddepartmentofthebraziliansocietyofendocrinologyandmetabolismsbem
_version_ 1756441469600661504